Sulfathiazole treats type 2 diabetes by restoring metabolism through activating CYP19A1

Hu, Zhuozhou; Li, Chun; Wu, Tongyu; Zhou, Jing; Han, Liang; Liu, Jingjing; Qiang, Shaojia; Zhao, Wenyang; Li, Xiangxiang; Liu, Xiaohua; Li, Jiazhong; Chen, Xinping

doi:10.1016/j.bbagen.2023.130303

Cited by 1 publication

(1 citation statement)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…An estrogen deficiency is closely related to insulin resistance and subsequent damage in the pancreas, liver, muscles, and adipose tissue. Sulindac can treat diabetes in mice by activating CYP19A1 to synthesize estrogen [55], and multiple clinical data show that the CYP19A1 gene deeply affects plasma zinc levels, urinary zinc levels, susceptibility, and other issues in Chinese type 2 diabetic populations [56,57]. PPARα is mainly expressed in metabolically active tissues and is not only used for treating dyslipidemia [58] but also for regulating glucose metabolism [59], maintaining vascular endothelial function balance in diabetes [60], protecting diabetic patients' visual nerves, inhibiting oxidative stress, anti-inflammatory, anti-diabetic kidney fibrosis, promoting neural repair, improving neural microcirculation, and reducing vascular regeneration injury, all of which play an important role in the chronic complications of diabetes [61][62][63].…”

Section: Discussionmentioning

confidence: 99%

Hypoglycemic Effects and Quality Marker Screening of Dendrobium nobile Lindl. at Different Growth Years

Luo,

Yang,

et al. 2024

Molecules

View full text Add to dashboard Cite

(1) Background: The effect of Dendrobium nobile Lindl. (D. nobile) on hyperglycemic syndrome has only been recently known for several years. Materials of D. nobile were always collected from the plants cultivated in various growth ages. However, regarding the efficacy of D. nobile on hyperglycemic syndrome, it was still unknown as to which cultivation age would be selected. On the other hand, with the lack of quality markers, it is difficult to control the quality of D. nobile to treat hyperglycemic syndrome. (2) Methods: The effects of D. nobile cultivated at year 1 and year 3 were checked on alloxan-induced diabetic mice while their body weight, diet, water intake, and urinary output were monitored. Moreover, levels of glycosylated serum protein and insulin were measured using Elisa kits. The constituents of D. nobile were identified and analyzed by using UPLC-Q/trap. Quality markers were screened out by integrating the data from UPLC-Q/trap into a network pharmacology model. (3) Results: The D. nobile cultivated at both year 1 and year 3 showed a significant effect on hyperglycemic syndrome at the high dosage level; however, regarding the significant level, D. nobile from year 1 showed the better effect. In D. nobile, most of the metabolites were identified as alkaloids and sesquiterpene glycosides. Alkaloids, represented by dendrobine, were enriched in D. nobile from year 1, while sesquiterpene glycosides were enriched in D. nobile from year 3. Twenty one metabolites were differentially expressed between D. nobile from year 1 and year 3. The aforementioned 21 metabolites were enriched to 34 therapeutic targets directly related to diabetes. (4) Conclusions: Regarding the therapy for hyperglycemic syndrome, D. nobile cultivated at year 1 was more recommended than that at year 3. Alkaloids were recommended to be used as markers to control the quality of D. nobile for hyperglycemic syndrome treatment.

show abstract